1[1]Kasper C, Terhaar A, Fossa A, et al. Recombinant human erythropoietin in the treatment of cancer - related anaemia.Eur J Haematol,1997; 58(4): 251
2[2]Ludwig H, Fritz E. Anemia of cancer patients: patient selection and patient stratification for epoetin treatment. Semin Oncol,1998 ;25 (3 suppl 7):35
3[3]Thatcher N. Management of chemotherapy - induced anemia in solid tumors. Semin Oncol, 1998 ;25 (3 suppl 7) :23
4[4]Kurz C, Marth C, Windbichler G, et al. Erythropoietin treatment under polychemotherapy in patients with gynecologic malignancies: a prospective, randomized, doubleblind placebo - controlled multicenter study. Gynecol Oncol,1997;65(3): 461
5[5]Ozguroglu M, Arun B, Demir G, et al. Serum erythropoietin level in anemic cancer patients. Med Oncol ,2000; 17 ( 1 ):29
6[6]Fjornes T, Wiedemann GJ, Sack K et al. Serum erythropoietin and creatinine concentrations as predictive factors for response to recombinant human erythropoietin treatment in anaemic tumour patients on chemotherapy. Oncol Rep, 1998;5(1): 81
7[7]Rosso R, et al: Use of erythropoietin in oncology. Tumori,1997;83(4 Suppl 2): s26
8[8]Tomoko Matsumoto, et al: Effect of recombinant human erythropoietin on anticancer drug - induced anemia. British Journal Haematology, 1990 ;75:463
9[9]Edson de Campos, et al. Clinical and In vitro effects of recombinant human erythropoietin in patients rrrceiving Intensive chemotherapy for small - cell lung cancer. Journal of Clinical Oncology, 1995; 13 (7): 1623
10[10]Leon P, et al. Recombinant human erythropoietin for the treatment of anemia in children with solid malignant tumors.Med Pediatr Oncol,1998; 30(2) :110
